23andMe SPAC Presentation Deck

Virgin's Investment Thesis for 23and Me Disrupting the Healthcare experience. 23andMe is building a personalized health and wellness experience that caters uniquely to the individual by harnessing the power of their DNA 2 The world's premier re-contactable genetic database. A vast proprietary dataset rich with both genotypic and phenotypic information allows insights that unlock revenue streams across digital health, therapeutics, and much more 3 Recognized and trusted brand with leading engagement metrics. Impressive repeat customer engagement validates the 23andMe platform and the demand for genetics-based consumer service 4 Institutionally sponsored therapeutics efforts. A broad pipeline established in collaboration with GSK validates the approach of developing novel therapeutics using genetic data 5 Multiple avenues for value creation. The FDA-approved consumer platform, the therapeutics efforts, and the rich database each create optionality for outsized value creation that is difficult to replicate 6 A world-class management team. Pioneers in their industries, the team has a long track record of success and value creation 23andMe Confidential and Proprietary Information 2

View entire presentation